HeartBeat Podcast

Mohammed Al-Qadami
  • 0.0 (0)
  • MEDICINE
  • UPDATED DAILY

Welcome to the HeartBeat Podcast, your trusted source for the latest discoveries and advancements in cardiology. This podcast leverages advanced AI tools to analyze, summarize, and transform cutting-edge medical research into high-quality podcast episodes. While artificial intelligence plays a key role in producing and presenting these episodes, the content is carefully curated and crafted to ensure accuracy, reliability, and clarity. Whether you're a doctor, a student, or someone passionate about cardiology, this podcast offers insightful and inspiring episodes that combine the power of tec

  1. 02/16/2025

    Impella CP: Can Microaxial Flow Pumps Redefine Cardiogenic Shock Treatment? Insights from the DanGer Shock Study

    In this episode, we explore the DanGer Shock study, which investigated the efficacy of the microaxial flow pump Impella CP in reducing mortality and improving clinical outcomes in patients with STEMI-related cardiogenic shock. We delve into the study's design, statistical findings, clinical recommendations, and the future of mechanical circulatory support in cardiology, highlighting both the benefits and risks of this advanced technology as published in the NEJM. Links to the Podcast Apple Podcast:⁠⁠⁠Listen on Apple Podcast⁠⁠⁠ Spotify:⁠⁠⁠Listen on Spotify⁠⁠⁠ Amazon Music:⁠⁠⁠Listen on Amazon Music⁠⁠⁠ YouTube:⁠⁠⁠Watch on YouTube⁠⁠⁠ 📚 Source:Study Title: Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock (DanGer Shock Trial)Publication Date: April 2024Journal: NEJMDOI:10.1056/NEJMoa2312572 #MedicalPodcast #Cardiology #CardiogenicShock #ImpellaCP #DanGerShockStudy #MyocardialInfarction #MicroaxialFlowPump #CirculatorySupport #NEJM #HeartFailure #ClinicalResearch #HeartDevices #Podcast

    11 min

  2. 02/09/2025

    Breathing Easier: How Aficamten is Giving New Hope to HCM Patients

    In this episode, we dive into the lives of patients with hypertrophic cardiomyopathy (HCM) and how Aficamten is offering them hope for a better future. From breathing easier to avoiding surgery, we’ll uncover the real impact of this new treatment backed by the SEQUOIA-HCM trial. If you care about heart health or know someone living with HCM, this one’s for you. Links to the Podcast Apple Podcast:⁠⁠Listen on Apple Podcast⁠⁠Spotify:⁠⁠Listen on Spotify⁠⁠Amazon Music:⁠⁠Listen on Amazon Music⁠⁠YouTube:⁠⁠Watch on YouTube⁠⁠ 📝Source: Study Title: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM Trial) Publication Date: May 13, 2024 NEJM.org - SEQUOIA-HCM Trial 🔗Full Study Details:NEJM - SEQUOIA-HCM Study🔗ClinicalTrials.gov:SEQUOIA-HCM NCT05186818 #BreathingEasier #HeartHealth #Aficamten #NewHope #SEQUOIAHCM #CardiologyTalk #Podcast #RealImpact #MedicalBreakthroughs #BetterLiving

    16 min

  3. 02/02/2025

    Empagliflozin’s Impact: Long-Term Cardiorenal Protection for CKD Patients

    In this episode, we explore the groundbreaking results of the EMPA-KIDNEY trial, a large-scale clinical study that highlights the long-term benefits of Empagliflozin (SGLT2 inhibitor) in patients with chronic kidney disease (CKD). We dive into how the treatment slowed disease progression, reduced cardiovascular deaths, and provided lasting benefits even after the therapy ended. Join us as we break down the study’s key findings, discuss their real-world implications, and uncover what makes this treatment a game-changer for CKD management. 🔗 Full Study Details: NEJM - EMPA-KIDNEY Study🔗 ClinicalTrials.gov: EMPA-KIDNEY NCT03594110 Links to the Podcast Apple Podcast: ⁠Listen on Apple Podcast⁠ Spotify: ⁠Listen on Spotify⁠ Amazon Music: ⁠Listen on Amazon Music⁠ YouTube: ⁠Watch on YouTube⁠ #Podcast #Empagliflozin #ChronicKidneyDisease #CKDManagement #EMPA_KIDNEY_Study #SGLT2Inhibitors #RenalHealth #CardioRenalProtection #ClinicalResearch #MedicalBreakthroughs #LongTermBenefits

    16 min

  4. 01/26/2025

    Beta-Blockers After Myocardial Infarction: To Stop or Continue? The ABYSS Study Unveiled

    In this episode of the Heartbeat Podcast, we explore the groundbreaking ABYSS trial, which investigates the controversial topic of beta-blocker therapy in patients with a history of myocardial infarction. Should beta-blockers be continued indefinitely, or is it safe to discontinue them after stabilization? Join us as we delve into the study's methods, findings, and implications for clinical practice. We discuss key outcomes, such as cardiovascular events and quality of life, to provide a comprehensive understanding of this pivotal research. Listen now to discover how this study could reshape post-myocardial infarction care and spark new discussions in cardiology. Links to the Podcast Apple Podcast: Listen on Apple Podcast Spotify: Listen on Spotify Amazon Music: Listen on Amazon Music YouTube: Watch on YouTube #Cardiology #ABYSSStudy #BetaBlockers #MyocardialInfarction #CardiacCare #ClinicalResearch #HeartHealth #MedicalPodcast #CardiovascularDisease #HealthcareProfessionals

    17 min

  5. 01/19/2025

    The Impact of Mineralocorticoid Receptor Antagonists on Heart Failure: A Comprehensive Meta-Analysis

    Discover the transformative role of Mineralocorticoid Receptor Antagonists (MRAs) in heart failure management. This episode delves into a comprehensive meta-analysis, showcasing their impact on reducing hospitalizations and cardiovascular deaths across various heart failure types, including preserved and reduced ejection fractions. Join us as we uncover the clinical significance of MRAs and their role in advancing cardiology practices. Tune in now and elevate your understanding of cutting-edge heart failure therapies." 🎧 Listen to this episode on your favorite platform: Apple Podcasts: Heartbeat Podcast on Apple Podcasts Spotify: Heartbeat Podcast on Spotify Amazon Music: Heartbeat Podcast on Amazon Music YouTube: Heartbeat Podcast on YouTube #HeartbeatPodcast #HeartFailure #Cardiology #MedicalResearch #MRAs #MineralocorticoidReceptorAntagonists #HeartHealth #PodcastForDoctors #MedicalPodcast #CardiovascularHealth

    19 min

  6. 01/12/2025

    Semaglutide and Heart Failure with Preserved Ejection Fraction: Key Findings

    In this episode of the Heartbeat Podcast, we delve into the latest findings from a pooled analysis of pivotal clinical trials—SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM. This study uncovers the impact of semaglutide, a GLP-1 receptor agonist, on patients with heart failure with preserved ejection fraction (HFpEF), particularly those struggling with obesity. Join us as we explore how this treatment reduces heart failure events and discuss its implications for clinical practice. With HFpEF being a challenging condition to treat, this episode highlights hope for patients and clinicians alike. Stay tuned for an insightful discussion, statistics, and the potential future of HFpEF management! Listen to the Episode Here: Apple Podcasts: Heartbeat Podcast on Apple Spotify: Heartbeat Podcast on Spotify Amazon Music: Heartbeat Podcast on Amazon YouTube: Heartbeat Podcast on YouTube #HFpEF #HeartFailure #Semaglutide #MedicalResearch #Cardiology #HeartHealth #Obesity #Podcast #MedicalScience #GLP1ReceptorAgonist#SELECTStudy #FLOWTrial #STEP_HFpEF #STEP_HFpEF_DM

    17 min

  7. 01/05/2025

    The Power of Blood Pressure Control: A Step Towards Better Health

    This episode highlights a pivotal study published in The New England Journal of Medicine that demonstrates how intensive blood pressure management can greatly reduce the risk of heart disease and stroke, especially for individuals with Type 2 Diabetes. By targeting a systolic blood pressure below 120 mm Hg, researchers found significant health benefits compared to the standard target of 140 mm Hg. Join us to uncover the practical implications of this research and its potential to transform lives. Links: Apple Podcasts: Heartbeat Podcast on Apple Spotify: Heartbeat Podcast on Spotify Amazon Music: Heartbeat Podcast on Amazon Music YouTube: Heartbeat Podcast on YouTube #DiabetesCare #BloodPressure #MedicalBreakthrough #HeartHealth #Cardiology #Type2Diabetes #MedicalPodcast #ResearchMatters #MedicalPodcast #HealthTips #PreventiveCare #HealthyLiving

    12 min

  8. 12/29/2024

    Finerenone and Heart Failure: A New Hope for Patients with Preserved Ejection Fraction

    In this episode of the "Heartbeat Podcast," we delve into groundbreaking research published in the New England Journal of Medicine on the efficacy of Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, for patients with heart failure and mildly reduced or preserved ejection fraction. Discover how this therapy reduces the risk of worsening heart failure events and cardiovascular mortality, and explore its implications for clinical practice. Join us for an in-depth discussion tailored for healthcare professionals and cardiologists seeking the latest advancements in cardiac care. #HeartbeatPodcast #HeartFailure #Cardiology #Finerenone #MedicalResearch #CardiacCare #PodcastForDoctors #MedicalPodcast Amazon Music: Listen on Amazon Music Apple Podcasts: Listen on Apple Podcasts Spotify: Listen on Spotify YouTube: Watch on YouTube

    17 min
See All (15)

About

Welcome to the HeartBeat Podcast, your trusted source for the latest discoveries and advancements in cardiology. This podcast leverages advanced AI tools to analyze, summarize, and transform cutting-edge medical research into high-quality podcast episodes. While artificial intelligence plays a key role in producing and presenting these episodes, the content is carefully curated and crafted to ensure accuracy, reliability, and clarity. Whether you're a doctor, a student, or someone passionate about cardiology, this podcast offers insightful and inspiring episodes that combine the power of tec

Information

  • Creator
    Mohammed Al-Qadami
  • Years Active
    2024 - 2025
  • Episodes
    15
  • Rating
    Clean
  • Copyright
    © Mohammed Al-Qadami
  • Show Website
    HeartBeat Podcast